A Pilot Study of Etanercept in Dermatomyositis

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Dermatomyositis
Interventions
DRUG

Etanercept

Etanercept 50 mg will be injected subcutaneously once per week for 52 weeks

DRUG

Placebo

Placebo, contained in 50mg syringes, will be injected subcutaneously once per week for 52 weeks.

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Brigham and Women's Hospital

OTHER